Duke University’s MURDOCK Study and Duke Clinical Research Institute (DCRI) will collaborate with Boehringer Ingelheim Pharmaceuticals on a new chronic obstructive pulmonary disease (COPD) study.
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Durham startup is working with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback